XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC....
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- THE 36TH ANNUAL TOMPKINS SQUARE HALLOWEEN DOG PARADE RETURNS ON OCTOBER 17
- Sagent Pharmaceuticals Launches Zyogreen®, the First and Only Ready-to-Use Indocyanine Green Injection in the U.S.
- Embry‑Riddle Earns Eight Top-Five U.S. News Rankings, Including in Best Overall
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →